BibTex RIS Cite

Pathological Complete Response After Imatinib Mesylate Therapy in Inoperabl Gastrointestinal Stromal Tumor: A Case Report

Year 2011, Volume: 16 Issue: 4, 206 - 208, 01.08.2011

Baha Zengel Ahmet Alacacıoglu Ayse Yagcı Hakan Postacı Ozgur Kavak Ali Galip Erhan Gokmen

Abstract

Gastrointestinal stromal tumors are characterized by the expression of CD34 and c-kit (CD117) and represent the most common mesenchymal malignancy of the gastrointestinal tract. Imatinib mesylate is small molecule tyrosine kinase inhibitor that suppresses transmembrane receptor c-kit products. Clinical studies for metastatic and inoperabl GISTs have demonstrated partial response rate ranging from 40% to 69% in patients treated with imatinib mesylate. But complete response is rare. We present a 46 year old man patient with unresectable gastrointestinal stromal tumor that has histopatologically proven complete response to imatinib mesylate therapy.

Keywords

-

References

  • Demetri GD. Gastrointestinal stromal tumor. In: Cancer: Principles and practice of oncology, 8th ed, DeVita VT, Hellman S, Rosenberg SA (Eds), p 1257, Lippincott-Williams &Wilkins, Philadelphia, 2008.
  • Mazur MT, Clark HB. Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol 1983; 7: 507-519.
  • Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristic of the intersititial cell of Cajal. Am J Pathol 1998; 152: 1259-1269.
  • Chiang KC, Chen TW, Yeh CN, Liu FY, Lee HL, Jan YY. Advanced gastrointestinal stromal tumor patients with complete response after treatment with imatinib mesylate. World J Gastroenterol 2006; 12: 2060-2064.
  • Melichar B, Voboril Z, Nozicka J, et al. Pathological complete response in advanced gastrointestinal stromal tumor after imatinib therapy. Internal Medicine 2005; 44: 1163-1168.
  • Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Eng J Med 2001; 344: 1052- 1056.
  • Andtbacka RH, Ng CS, Scaife CL, et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol 2007; 14: 14-24.
  • Gronchi A, Fiore M, Miselli F, et al. Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg 2007; 245: 341-346.
  • Nishida T, Shirao K, Sawaki A, et al. Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202). Int J Clin Oncol 2008; 13: 244-251.
  • Goh BK, Chow PK, Chuah KL, Yap WM, Wong WK. Pathologic, radiologic and PET scan response of gastrointestinal stromal tumors after neoadjuvant treatment with imatinib mesylate. Eur J Surg Oncol 2006; 32: 961-963.
  • Salazar M, Barata A, André S, et al. First report of a complete pathological response of a pelvic GIST treated with imatinib as neoadjuvant therapy.Gut. 2006; 55: 585-586.
  • Suzuki S, Sasajima K, Miyamoto M, et al. Pathologic complete response confirmed by surgical resection for liver metastases of gastrointestinal stromal tumor after treatment with imatinib mesylate. World J Gastroenterol 2008; 14: 3763- 3767.
  • Gönderilme Tarihi: 01.12.2010

Inoperabl Gastrointestinal Tümörde Imatinib Mesilat Tedavisi Sonrası Patolojik Tam Yanıt: Olgu Sunumu

Year 2011, Volume: 16 Issue: 4, 206 - 208, 01.08.2011

Baha Zengel Ahmet Alacacıoglu Ayse Yagcı Hakan Postacı Ozgur Kavak Ali Galip Erhan Gokmen

Abstract

Gastrointestinal stromal tümörler CD34 and c-kit (CD117) ekspresyonu ile karekterize olan, gastrointestinal sistemin en sık görülen mezenkimal maligniteleridir. İmatinib mesiat, transmembran reseptör c-kit ürünlerini baskılayan küçük molekül tirozin kinaz inhibitörüdür. Metastatik ve inoperabl gastarointestinal stromal tümörlerde yapılan klinik çalışmalarda imatinib mesilat tedavisi ile parsiyel yanıt oranları 40% ile 69% arasındadır. Fakat tam yanıt nadirdir. Bu yazımızda 46 yaşında anrezektabl gastrointestinal stromal tümorlü erkek hastada, imatinib mesilat tedavisi ile sağlanan patolojik tam yanıt değerlendirilmiştir.

Keywords

Gastrointestinal stromal tümor Imatinib mesylate Patalojik tam yanıt Cerrahi

References

  • Demetri GD. Gastrointestinal stromal tumor. In: Cancer: Principles and practice of oncology, 8th ed, DeVita VT, Hellman S, Rosenberg SA (Eds), p 1257, Lippincott-Williams &Wilkins, Philadelphia, 2008.
  • Mazur MT, Clark HB. Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol 1983; 7: 507-519.
  • Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristic of the intersititial cell of Cajal. Am J Pathol 1998; 152: 1259-1269.
  • Chiang KC, Chen TW, Yeh CN, Liu FY, Lee HL, Jan YY. Advanced gastrointestinal stromal tumor patients with complete response after treatment with imatinib mesylate. World J Gastroenterol 2006; 12: 2060-2064.
  • Melichar B, Voboril Z, Nozicka J, et al. Pathological complete response in advanced gastrointestinal stromal tumor after imatinib therapy. Internal Medicine 2005; 44: 1163-1168.
  • Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Eng J Med 2001; 344: 1052- 1056.
  • Andtbacka RH, Ng CS, Scaife CL, et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol 2007; 14: 14-24.
  • Gronchi A, Fiore M, Miselli F, et al. Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg 2007; 245: 341-346.
  • Nishida T, Shirao K, Sawaki A, et al. Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202). Int J Clin Oncol 2008; 13: 244-251.
  • Goh BK, Chow PK, Chuah KL, Yap WM, Wong WK. Pathologic, radiologic and PET scan response of gastrointestinal stromal tumors after neoadjuvant treatment with imatinib mesylate. Eur J Surg Oncol 2006; 32: 961-963.
  • Salazar M, Barata A, André S, et al. First report of a complete pathological response of a pelvic GIST treated with imatinib as neoadjuvant therapy.Gut. 2006; 55: 585-586.
  • Suzuki S, Sasajima K, Miyamoto M, et al. Pathologic complete response confirmed by surgical resection for liver metastases of gastrointestinal stromal tumor after treatment with imatinib mesylate. World J Gastroenterol 2008; 14: 3763- 3767.
  • Gönderilme Tarihi: 01.12.2010
There are 13 citations in total.

Details

Primary Language Turkish
Journal Section Articles
Authors

Baha Zengel This is me

Ahmet Alacacıoglu This is me

Ayse Yagcı This is me

Hakan Postacı This is me

Ozgur Kavak This is me

Ali Galip This is me

Erhan Gokmen This is me

Publication Date August 1, 2011
Published in Issue Year 2011 Volume: 16 Issue: 4

Cite

APA Zengel, B., Alacacıoglu, A., Yagcı, A., Postacı, H., et al. (2011). Inoperabl Gastrointestinal Tümörde Imatinib Mesilat Tedavisi Sonrası Patolojik Tam Yanıt: Olgu Sunumu. Fırat Tıp Dergisi, 16(4), 206-208.
AMA Zengel B, Alacacıoglu A, Yagcı A, Postacı H, Kavak O, Galip A, Gokmen E. Inoperabl Gastrointestinal Tümörde Imatinib Mesilat Tedavisi Sonrası Patolojik Tam Yanıt: Olgu Sunumu. Fırat Tıp Dergisi. August 2011;16(4):206-208.
Chicago Zengel, Baha, Ahmet Alacacıoglu, Ayse Yagcı, Hakan Postacı, Ozgur Kavak, Ali Galip, and Erhan Gokmen. “Inoperabl Gastrointestinal Tümörde Imatinib Mesilat Tedavisi Sonrası Patolojik Tam Yanıt: Olgu Sunumu”. Fırat Tıp Dergisi 16, no. 4 (August 2011): 206-8.
EndNote Zengel B, Alacacıoglu A, Yagcı A, Postacı H, Kavak O, Galip A, Gokmen E (August 1, 2011) Inoperabl Gastrointestinal Tümörde Imatinib Mesilat Tedavisi Sonrası Patolojik Tam Yanıt: Olgu Sunumu. Fırat Tıp Dergisi 16 4 206–208.
IEEE B. Zengel, A. Alacacıoglu, A. Yagcı, H. Postacı, O. Kavak, A. Galip, and E. Gokmen, “Inoperabl Gastrointestinal Tümörde Imatinib Mesilat Tedavisi Sonrası Patolojik Tam Yanıt: Olgu Sunumu”, Fırat Tıp Dergisi, vol. 16, no. 4, pp. 206–208, 2011.
ISNAD Zengel, Baha et al. “Inoperabl Gastrointestinal Tümörde Imatinib Mesilat Tedavisi Sonrası Patolojik Tam Yanıt: Olgu Sunumu”. Fırat Tıp Dergisi 16/4 (August 2011), 206-208.
JAMA Zengel B, Alacacıoglu A, Yagcı A, Postacı H, Kavak O, Galip A, Gokmen E. Inoperabl Gastrointestinal Tümörde Imatinib Mesilat Tedavisi Sonrası Patolojik Tam Yanıt: Olgu Sunumu. Fırat Tıp Dergisi. 2011;16:206–208.
MLA Zengel, Baha et al. “Inoperabl Gastrointestinal Tümörde Imatinib Mesilat Tedavisi Sonrası Patolojik Tam Yanıt: Olgu Sunumu”. Fırat Tıp Dergisi, vol. 16, no. 4, 2011, pp. 206-8.
Vancouver Zengel B, Alacacıoglu A, Yagcı A, Postacı H, Kavak O, Galip A, Gokmen E. Inoperabl Gastrointestinal Tümörde Imatinib Mesilat Tedavisi Sonrası Patolojik Tam Yanıt: Olgu Sunumu. Fırat Tıp Dergisi. 2011;16(4):206-8.